525 related articles for article (PubMed ID: 34473544)
1. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Hamanishi J; Takeshima N; Katsumata N; Ushijima K; Kimura T; Takeuchi S; Matsumoto K; Ito K; Mandai M; Nakai H; Sakuragi N; Watari H; Takahashi N; Kato H; Hasegawa K; Yonemori K; Mizuno M; Takehara K; Niikura H; Sawasaki T; Nakao S; Saito T; Enomoto T; Nagase S; Suzuki N; Matsumoto T; Kondo E; Sonoda K; Aihara S; Aoki Y; Okamoto A; Takano H; Kobayashi H; Kato H; Terai Y; Takazawa A; Takahashi Y; Namba Y; Aoki D; Fujiwara K; Sugiyama T; Konishi I
J Clin Oncol; 2021 Nov; 39(33):3671-3681. PubMed ID: 34473544
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
[TBL] [Abstract][Full Text] [Related]
3. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Lorusso D; Pignata S; Breda E; Savarese A; Del Medico P; Scaltriti L; Katsaros D; Priolo D; Scambia G
J Clin Oncol; 2008 Feb; 26(6):890-6. PubMed ID: 18281662
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
8. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Mutch DG; Orlando M; Goss T; Teneriello MG; Gordon AN; McMeekin SD; Wang Y; Scribner DR; Marciniack M; Naumann RW; Secord AA
J Clin Oncol; 2007 Jul; 25(19):2811-8. PubMed ID: 17602086
[TBL] [Abstract][Full Text] [Related]
11. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
12. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
13. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
14. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Alberts DS; Liu PY; Wilczynski SP; Clouser MC; Lopez AM; Michelin DP; Lanzotti VJ; Markman M;
Gynecol Oncol; 2008 Jan; 108(1):90-4. PubMed ID: 17949799
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
Ferrandina G; Paris I; Ludovisi M; D'Agostino G; Testa A; Lorusso D; Zanghi M; Pisconti S; Pezzella G; Adamo V; Breda E; Scambia G
Gynecol Oncol; 2005 Aug; 98(2):267-73. PubMed ID: 15975643
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
